...
...
Next Story

Bharat Biotech lowers vaccine price for states

The vaccine manufacturer’s decision to slash the price by 33% came a a day after another Covid-19 vaccine manufacturer, Serum Institute of India (SII), which makes the Oxford-AstraZeneca vaccine under the brand name Covishield in India, reduced its selling price to states to ₹300 from ₹400.

Published on: Apr 30, 2021, 02:26:35 IST
Advertisement

Bharat Biotech, the co-developer and manufacturer of India’s indigenous coronavirus disease vaccine, Covaxin, on Thursday announced a revised selling price of ₹400 per dose, from the earlier ₹600, for state governments.

A health worker prepares a dose of Bharat Biotech Ltd. Covaxin vaccine for coronavirus at Sanjeevan Hospital in Daryaganj, New Delhi, India. (Bloomberg)
A health worker prepares a dose of Bharat Biotech Ltd. Covaxin vaccine for coronavirus at Sanjeevan Hospital in Daryaganj, New Delhi, India. (Bloomberg)

The vaccine manufacturer’s decision to slash the price by 33% came a a day after another Covid-19 vaccine manufacturer, Serum Institute of India (SII), which makes the Oxford-AstraZeneca vaccine under the brand name Covishield in India, reduced its selling price to states to ₹300 from ₹400.

“Bharat Biotech is deeply concerned with the critical pandemic circumstances that India is facing at this time. Recognising the enormous challenges to the public health care system, we have made Covaxin available to state governments at a price of ₹400 per dose,” the company said in a statement.

“We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally intensive BSL-3 manufacturing facilities (the first of its kind in our country) and clinical trials. We wish to champion innovation in India and our commitment to public health is absolute,” the statement added.

The decisions by the two companies come amid demands from several states that the vaccine prices for them be reduced, and be brought at par with the price for the Union government, which buys the two vaccines from SII and Bharat Biotech for ₹150 a dose.

Several chief ministers, including Delhi’s Arvind Kejriwal and Maharashtra’s Uddhav Thackeray, have demanded a “one nation, one price” policy.

But the companies have stressed that the revenue generated from sale is important for them to expand production capacities.

Bharat Biotech has a production capacity of about 10 million Covaxin doses each month, and is looking at manufacturing scale up in a stepwise manner across multiple facilities at Hyderabad and Bangalore.

With the help of the Union government, the company is working towards ramping up the production capacity by at least 100% by May-June, 2021, and with a target set of producing nearly 100 million doses per month by September 2021. The Union finance ministry also approved a credit line of ₹1,500 crore to Bharat Biotech for this purpose.

 
ABOUT THE AUTHOR
Rhythma Kaul

Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.

Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
Get Latest News, breaking headlines, and top India News, and today real-time updates from across the nation. Stay informed on politics, government policies, crime, Today Weather, and major developments on Hindustan Times
SHARE THIS ARTICLE ON
Notifications

Get breaking alerts directly from the newsroom

Notifications are on!You'll be notified when news breaks